CAR T Cell Therapy Shows Tumour Regression and Neurological Improvement in H3K27M-mutated diffuse midline gliomas (DMGs).
Time to read: 07:20. . This Phase 1 study of GD2-targeted CAR T-cell therapy showed promising clinical and imaging benefits in children with H3K27M-mutated diffuse midline gliomas (DMGs),
